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Background
Replicating viral vectors are promising HIV vaccine can-
didates that may enhance immunogenicity through pro-
longed antigen expression. VSV is the first replicating
viral vector after vaccinia to be tested clinically as an HIV
vaccine; here we present preliminary safety and immuno-
genicity data from a phase 1a trial.
Methods
HVTN 090 enrolled sixty healthy, HIV-1-uninfected
adults in a randomized, double-blinded, placebo-con-
trolled dose escalation study. Groups of 12 participants
received rVSV Indiana HIV Gag vaccine at 5 dose levels
(4.6 x 103 to 3.4 x 107 PFU) (N=10/group) or placebo
(N=2/group), delivered intramuscularly at 0 and 2
months. Reactogenicity over 7 days, adverse events
(AEs), and viral cultures from whole blood, urine, saliva
and swabs of oral lesions were collected. HIV-1-specific
CD4+ and CD8+ T-cell responses to Gag peptides were
measured 1 and 2 weeks post-boost by intracellular
cytokine staining.
Results
The study is ongoing and data are blinded. The median
age was 24; 47% were female and 37% were non-white.
Local and systemic reactogenicity was self-limited, mild
to moderate in intensity and increased with dose, with
headache reported most commonly (52%). At the highest
dose, 92% reported systemic symptoms, including flu-like
syndrome (41%), fever (41%), and moderate chills (33%).
Lymphadenopathy, decreased neutrophil count, oral
ulceration, and presyncope were each seen in > 1 partici-
pant. No severe reactogenicity, encephalitis, or product-
related SAEs were reported, and all VSV cultures were
negative at all doses tested. Low frequency HIV-specific
CD4+ (9%) and CD8+ (3%) T-cell responses were
detected post-boost at the first 3 dose levels.
Conclusion
Immunization with an attenuated, replicating rVSV Indi-
ana HIV-1 vaccine has an acceptable reactogencity and
safety profile to date. Preliminary data reveal few T-cell
responses at lower doses. Immunogenicity of the vaccine
at the highest doses and in heterologous prime-boost
regimens will guide future vector development.
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